Condition: Hematologic Malignancies · Hematopoietic Stem Cell Transplant (HSCT) · Sponsor: Pulmotect, Inc.
The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation with documented viral infections due to PIV, hMPV, or RSV. PUL-042 or a placebo will be administered 3 times over a 6-day period. The total duration of the study will be approximately 30 days.
This description comes directly from the study's public registry record.
Colin Broom, MD · 484 354 0615 · cbroom@pulmotect.com
Brenton Scott, Ph D · 713 579 9226 · bscott@pulmotect.com
Always discuss trial participation with your own doctor first.
| City of Hope National Medical Center | Duarte, California, United States | Recruiting |
| Northside Hospital | Atlanta, Georgia, United States | Recruiting |
| Johns Hopkins Hospital | Baltimore, Maryland, United States | Recruiting |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Recruiting |
| Barbara Ann Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| John Theurer Cancer Center | Hackensack, New Jersey, United States | Recruiting |
| Lineberger Cancer | Chapel Hill, North Carolina, United States | Recruiting |
| OU Health Physicians - Infectious Disease Clinic | Oklahoma City, Oklahoma, United States | Recruiting |
| University of Texas MD Anderson MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06665100